Orforglipron
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
Eli Lilly · Phase 3 · Active, not recruiting · Enrollment 487
No selected arm has a reported week for this endpoint.
A solid line connects the weeks the source reports.